Common members of PRCs and their alterations in cancer
| Human . | Mouse homolog . | Alteration in cancer . | Tumor type . |
|---|---|---|---|
| PRC1 complex | |||
| BMI1 | Bmi1 | Overexpression/amplification | Acute myeloid leukemia,155 Hodgkin lymphoma,5,102,103,113 B cell non-Hodgkin lymphoma,5,54,112,126 gastrointestinal tumors,5 pituitary adenoma,5 parathyroid adenoma,6 breast cancer,156 glioma,157 neuroblastoma,158 medulloblastoma,159 non-small-cell lung cancer,160 skin cancer161 |
| MEL18/RNF110/PCGF2 | Mel18 | Loss | Cutaneous squamous-cell carcinoma,6 gynecological tumors,5 prostate cancer158 |
| RING1A | Ring1a | Overexpression | Large B-cell lymphoma126 |
| Loss | Clear-cell renal-cell carcinoma and testicular germ-cell tumors5 | ||
| RNF2 | Ring1b | Overexpression | Gastric and colonic tumors,5 melanoma,5 lung cancer,5 gynecological tumors,5 diffuse large B-cell lymphoma,5 follicular lymphoma,5 Burkitt lymphoma,5 Hodgkin lymphoma5,102 |
| HPH1, HPH2, HPH3 | Rae28/Mph1, Phc2, Phc3 | Lack of expression | Acute lymphocytic leukemia162 |
| Overexpression | Large B-cell lymphoma,156 central nervous system tumors6 | ||
| CBX2, CBX4, CBX6, CBX7, CBX8 | M33/Cbx2, Cbx4, Cbx6, Cbx7, Cbx8 | Loss | Pancreatic cancer,159 aggressive thyroid carcinomas160 |
| Overexpression | Follicular lymphoma163 | ||
| PCGF6 | Pcgf6 | Loss | Mantle-cell lymphoma164 |
| RYBP | Rybp | Overexpression | Oligodendroglioma,5 pituitary adenoma,5 T cell lymphoma,5 Hodgkin Lymphoma5,102 |
| PRC2 complex | |||
| EZH2/EZH1 | Ezh2/Ezh1 | Overexpression/amplification | Prostate carcinoma,109,165 breast carcinoma,127,165,166 melanoma,160 bladder cancer,127,167 glioma,168 endometrial carcinoma,165 lymphomas,111,127 colon carcinoma,127 glioblastoma,127 Ewing tumor169 |
| Deletion/mutation | Lymphomas,114 myeloid malignancies117,118 | ||
| Altered localization | Acute myeloid leukemia104 | ||
| SUZ12 | Suz12 | Overexpression/amplification/translocation | Gastrointestinal tumors,108,170 lung tumors,108 thyroid follicular carcinoma,108 pituitary adenoma,108 parathyroid adenoma,108 skin tumors,108 breast and gynecological tumors,108,170 mantle-cell lymphoma,108 chronic myeloid leukemia,119 endometrial stromal tumor119 |
| EED | Eed | Overexpression | Salivary gland adenoid cystic carcinoma,171 Hodgkin lymphoma,103 prostate cancer6 |
| Lack of expression | Prostate cancer172 | ||
| RBBP7 | Rbbp7 | Overexpression | Non-small-cell lung cancer,173 breast cancer174 |
| RBBP4 | Rbbp4 | Down-regulation | Cervical cancer175 |
| PCL3 | Phf19 | Overexpression | Cancers of the colon, skin, lung, rectum, cervix, uterus, and liver 176 |
| Human . | Mouse homolog . | Alteration in cancer . | Tumor type . |
|---|---|---|---|
| PRC1 complex | |||
| BMI1 | Bmi1 | Overexpression/amplification | Acute myeloid leukemia,155 Hodgkin lymphoma,5,102,103,113 B cell non-Hodgkin lymphoma,5,54,112,126 gastrointestinal tumors,5 pituitary adenoma,5 parathyroid adenoma,6 breast cancer,156 glioma,157 neuroblastoma,158 medulloblastoma,159 non-small-cell lung cancer,160 skin cancer161 |
| MEL18/RNF110/PCGF2 | Mel18 | Loss | Cutaneous squamous-cell carcinoma,6 gynecological tumors,5 prostate cancer158 |
| RING1A | Ring1a | Overexpression | Large B-cell lymphoma126 |
| Loss | Clear-cell renal-cell carcinoma and testicular germ-cell tumors5 | ||
| RNF2 | Ring1b | Overexpression | Gastric and colonic tumors,5 melanoma,5 lung cancer,5 gynecological tumors,5 diffuse large B-cell lymphoma,5 follicular lymphoma,5 Burkitt lymphoma,5 Hodgkin lymphoma5,102 |
| HPH1, HPH2, HPH3 | Rae28/Mph1, Phc2, Phc3 | Lack of expression | Acute lymphocytic leukemia162 |
| Overexpression | Large B-cell lymphoma,156 central nervous system tumors6 | ||
| CBX2, CBX4, CBX6, CBX7, CBX8 | M33/Cbx2, Cbx4, Cbx6, Cbx7, Cbx8 | Loss | Pancreatic cancer,159 aggressive thyroid carcinomas160 |
| Overexpression | Follicular lymphoma163 | ||
| PCGF6 | Pcgf6 | Loss | Mantle-cell lymphoma164 |
| RYBP | Rybp | Overexpression | Oligodendroglioma,5 pituitary adenoma,5 T cell lymphoma,5 Hodgkin Lymphoma5,102 |
| PRC2 complex | |||
| EZH2/EZH1 | Ezh2/Ezh1 | Overexpression/amplification | Prostate carcinoma,109,165 breast carcinoma,127,165,166 melanoma,160 bladder cancer,127,167 glioma,168 endometrial carcinoma,165 lymphomas,111,127 colon carcinoma,127 glioblastoma,127 Ewing tumor169 |
| Deletion/mutation | Lymphomas,114 myeloid malignancies117,118 | ||
| Altered localization | Acute myeloid leukemia104 | ||
| SUZ12 | Suz12 | Overexpression/amplification/translocation | Gastrointestinal tumors,108,170 lung tumors,108 thyroid follicular carcinoma,108 pituitary adenoma,108 parathyroid adenoma,108 skin tumors,108 breast and gynecological tumors,108,170 mantle-cell lymphoma,108 chronic myeloid leukemia,119 endometrial stromal tumor119 |
| EED | Eed | Overexpression | Salivary gland adenoid cystic carcinoma,171 Hodgkin lymphoma,103 prostate cancer6 |
| Lack of expression | Prostate cancer172 | ||
| RBBP7 | Rbbp7 | Overexpression | Non-small-cell lung cancer,173 breast cancer174 |
| RBBP4 | Rbbp4 | Down-regulation | Cervical cancer175 |
| PCL3 | Phf19 | Overexpression | Cancers of the colon, skin, lung, rectum, cervix, uterus, and liver 176 |
Bold text indicates members known to be frequently altered in cancer.